Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 5, 2014, Pages

  Hung, W Y ^a,b   Yu, M C ^a,c   Chiang, Y C ^a,d   Chang, J H ^a   Chiang, C Y ^a   Chang, C C ^c,e   Chuang, H C ^c,e   Bai, Kuan Jen ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cycloserine; MDR TB; Therapeutic drug monitoring; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; AGGRESSIVENESS; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PERSECUTORY DELUSION; PRIORITY JOURNAL; PSYCHOSIS; TAIWAN; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; DRUG MONITORING; INTESTINE ABSORPTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TERTIARY CARE CENTER; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CYCLOSERINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; TAIWAN; TERTIARY CARE CENTERS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84899575373     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0268     Document Type: Article

References (34)

1. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 1674: 603-662.
2. Peloquin C A. Tuberculosis drug serum levels. Clin Infect Dis 2001; 334: 584-585.
3. Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 6215: 2169-2183. (Pubitemid 35252827)
4. Peloquin C A. Serum concentrations of the antimycobacterial drugs. Chest 1998; 1135: 1154-1155. (Pubitemid 28223794)
5. Peloquin C A. Use of therapeutic drug monitoring in tuberculosis patients. Chest 2004; 1266: 1722-1724.
6. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 4010: 1481-1491. (Pubitemid 40628637)
7. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 16710: 1341-1347. (Pubitemid 36609717)
8. Nijland H M, Ruslami R, Stalenhoef J E, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006; 437: 848-854. (Pubitemid 44435511)
9. McIlleron H,Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 504: 1170-1177.
10. Perlman D C, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis, 2005; 4111: 1638-1647. (Pubitemid 41691604)
11. Peloquin C A, Namdar R, Dodge A A, et al. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 38: 703-710. (Pubitemid 29378471)
12. Peloquin C A, Namdar R, Singleton M D, et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 1151: 12-18. (Pubitemid 29047048)
13. Peloquin C A, Bulpitt A E, Jaresko G S, et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999; 433: 568-572. (Pubitemid 29109520)
14. Nix D E, Adam R D, Auclair B, et al., Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004; 846: 365-373. (Pubitemid 39451903)
15. Fukino K, Sasaki Y, Hirai S, et al. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 2008; 332: 187-195. (Pubitemid 351872360)
16. Donald P R, Parkin D P, Seifart H I, et al., The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007; 637: 633-639. (Pubitemid 46911342)
17. Mehta J B, Shantaveerapa H, Byrd R P, Jr, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 1205: 1520- 1524.
18. Zhu M, Burman W J, Jaresko G S, et al., Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 2001; 219: 1037-1045. (Pubitemid 32807864)
19. Peloquin C A, Hadad D J, Molino L P, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 523: 852-857. (Pubitemid 351358362)
20. Stambaugh J J, Berning S E, Bulpitt A E, et al. Ofloxacin population pharmacokinetics in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 66: 503-509. (Pubitemid 34601867)
21. Um SW, Lee SW, Kwon S Y, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007; 119: 972-978. (Pubitemid 47425023)
22. Peloquin C A, Jaresko G S, Yong C L, et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 4112: 2670-2679. (Pubitemid 27524738)
23. Burman W J, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 405: 327-341. (Pubitemid 32565595)
24. nd ed. San Francisco, CA, USA: National Tuberculosis Center and California Department of Public Health, University of California, 2008:
25. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
26. Levey A S, Bosch J P, Lewis J B, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 1306: 461-470. (Pubitemid 29135798)
27. Naranjo C A, Busto U, Sellers E M, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 302: 239-245. (Pubitemid 12149145)
28. Peloquin C A, Berning S E, Huitt G A, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999; 1593: 932-934. (Pubitemid 29137798)
29. Zhu M, Namdar R, Stambaugh J J, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002; 82: 91-96. (Pubitemid 35155424)
30. Lee H W, Kim D W, Park J H, et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 139: 1161-1166.
31. Zhu M, Nix D E, Adam R D, et al. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice and antacids. Pharmacotherapy 2001; 218: 891-897. (Pubitemid 32747309)
32. Perlman D C, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis 2004; 384: 556-564. (Pubitemid 38250967)
33. Pranger A D, Kosterink J G, van Altena R, et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 2011; 333: 350-354.
34. Alffenaar J W, Kosterink J G, van Altena R, et al. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010; 321: 97-101.